Navigation Links
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Date:12/9/2008

atients in this group could receive all six of the intended courses compared with an historic high-risk group treated with FCR. There was no significant difference in incidence of infection during treatment with CFAR compared to FCR, with the exception of cytomegalovirus (CMV) reactivation. Follow-up continues for the patients treated on this trial to evaluate responses in all 60 enrolled patients and time-to-event endpoints.

Abstract #329

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

The multicenter trial evaluated subcutaneous alemtuzumab given three times weekly at 30 mg in fludarabine refractory CLL. From September 2002 to February 2006, 103 patients were enrolled and received at least one dose of alemtuzumab. Median age was 63 years.

Subcutaneous treatment was performed on an outpatient basis in 96 percent of patients and had to be temporarily interrupted in 65 patients due to neutropenia (27 percent), anemia (three percent), thrombocytopenia (eight percent), infections (36 percent), and was stopped early in 65 cases due to insufficient response (43 percent), hematotoxicity (14 percent) and infections (29 percent). The median alemtuzumab dose given was 722 (3-2203) mg.

Toxicity observed during the treatment period was mostly grade 1/2 apart from hematotoxicity. Grade 3/4 neutropenia, thrombocytopenia, and anemia occurred in 56 percent, 57 percent, and 50 percent of patients, respectively. Grade 3/4 non-CMV infection occurred in 29 percent. CMV reactivation was observed in 15 percent total. Grade 3/4 occurred in eight percent of patients. All CMV episodes were successfully treated with anti-CMV therapy, and there was no CMV-related death. Injection site reactions occurred in 34 percent of patients and were grade 1 or 2 except in one patient
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... YORK , September 23, 2014 ... pioneer in computer-aided dysmorphology analysis will exhibit at the ... Diego, CA. FDNA will present the latest ... and reference solution, using facial analysis technology. Face2Gene facilitates ... of human malformations from facial photos. The ...
(Date:9/23/2014)... -- According to the new research ... Irreversible Electroporation, Cryotherapy, Microwave), Application (General & Cosmetic ... to 2019", published by MarketsandMarkets, studies the global Ablation ... to 2019. The market is expected to reach ... from 2014 to 2019. Browse 95 ...
(Date:9/23/2014)... Sept. 23, 2014  While proton therapy recently began in the ... Ashya King , another case in the United States ... young boy who was given just days to live now looks forward ... Green of Arizona complained of a headache ... medical treatments that will conclude Sept. 23, when he completes proton ...
Breaking Medicine Technology:FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online 2Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 45-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4
... with Betaseron(R),(interferon beta-1b) shortly after their first clinical ... risk of developing confirmed disability,progression compared to patients ... and published in The Lancet this,week-provide the first ... on later accumulation of disability, as observed,over the ...
... PHILADELPHIA, Aug. 3 GlaxoSmithKline (NYSE:,GSK), one of ... has placed another order to purchase bulk H5N1 ... The company also announced the,start of the first ... pre-pandemic influenza program. HHS Order The ...
Cached Medicine Technology:Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression 2Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression 3Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression 4Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression 5GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 2GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 3GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 4
(Date:9/23/2014)... If you or a loved one ... treatment may be a challenge. Fortunately, an inventor from ... is designed to improve the experience. , He developed ... having to remove, tear or reposition their clothing. Furthermore, ... their dignity. At the same time, it safeguards their ...
(Date:9/23/2014)... been shown to be a driving force behind ... develops due to chronic inflammation caused by conditions ... relatively few effective treatment options. Now, scientists at ... for the first time in preclinical studies that ... astrocyte elevated gene-1 (AEG-1) halts the development and ...
(Date:9/23/2014)... Becker's Hospital Review has published ... Hospitals and Health Systems With Great Orthopedic Programs." ... the list have orthopedic surgery departments, programs or ... reputable sources. Exceptional orthopedic departments include physicians who ... and treat professional athletes. , This is the ...
(Date:9/23/2014)... the curve of oxygen desaturation" (AUC Desat ) may ... levels during procedures using sedation, according to a study ... AUC Desat provides information not only whether blood ... duration, and rate of episodes of oxygen desaturation. ... of Cincinnati and colleagues reports on the development of ...
(Date:9/23/2014)... Contrary to what is often assumed about single parents, ... from The Kinsey Institute has found that single parents ... active as often as singles without children -- and ... The study, "Dating and Sexual Behavior Among Single Parents ... online in the Journal of Sex Research ...
Breaking Medicine News(10 mins):Health News:Apparel for Dialysis Patients Invented by InventHelp Client (CBA-2492) 2Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2
... vascular disease - a blood circulation problem that causes ... Saxton and other researchers from Sheffield Hallam University's centre ... patients aged between 50 and 85 with peripheral vascular ... cardiovascular function and walking ability of the patients improved ...
... HIV/AIDS spread – says Governor, Mr S C Jamir. ... the spread of HIV/AIDS, Governor adds. ,Many labourers ... tourist spot, bring with them the dreadful virus (HIV) when they ... Chinese proposal named ‘Four Frees and One Care’ meaning free anti-retroviral ...
... a vaccine to protect themselves from cervical cancer as the ... American pharmaceutical giant Merck. // ,The Food and ... for use in girls and women ages 9 to 26 ... of products with potential to provide significant benefits. , ...
... fertility treatment do not confide in their employers about the ... a survey carried out by the Infertility Network of ... observed that the patients were worried about not being able ... survey, done for National Infertility Day, revealed that although ...
... 1918 pandemic hit, the death toll was so overwhelming that ... to hold brief //memorial services, trains commandeered to transport dead ... Philadelphia. ,With the threat of another flu pandemic ... and health care providers making preparations for it mortuary specialists ...
... A new study in UK reports, parents believe more than ... one year old children are found //to avoid certain foods ... compulsion - Dr. Taraneh Dean of the University of Portsmouth ... Journal of Allergy and Clinical Immunology as only 2 – ...
Cached Medicine News:Health News:What to do with the Dead if a Flu Outbreak Happens? 2
... for the Humphrey Field Analyzer, SITA ... shows less inter-test variability than Full ... of reproducibility as Full Threshold SWAP. ... with the earlier glaucoma damage detected ...
... you can trust its capabilities will ... cataract, and glaucoma therapy in one ... is the optimal system for photocoagulation, ... iridotomy. The push of a button ...
... The VISUCAM non-mydriatic ... quality and simplicity of ... big enough to set ... photography, it features a ...
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
Medicine Products: